LAVA is offered in 2ml and 6ml options for the peripheral vasculature, along with viscosity options for the distal embolisation of small vessels that cannot be accessible through other embolic systems to treat controlled target vessel occlusion
Sirtex Medical rolls out LAVA LES. (Credit: ANIRUDH on Unsplash)
US-based medical device company Sirtex Medical has commercially rolled out its LAVA Liquid Embolic System (LES) to treat peripheral vascular haemorrhage.
LAVA LES is designed to provide volume and viscosity options that optimise the treatment of patients with controlled target vessel occlusion and is said to be the first and only liquid embolic system to receive regulatory approval.
It is offered in 2ml and 6ml options for the peripheral vasculature, along with viscosity options for the distal embolisation of small vessels that cannot be accessible through other embolics.
The pre-mixed vials are designed to provide both proximal target embolisation and distal target embolisation, with options to reach the bleed, said Sirtex.
Its 2ml option comprises two 1ml delivery syringes, while the 6ml option comprises six 1mL delivery syringes, facilitating multi-zone embolisation options from a single pre-mixed vial.
LAVA LES also comes with an optional Mixing Kit which suspends the radiopaque particles, designed to reduce flash for clear imaging, with the shaking of the vial.
Sirtex chief commercial officer Matt Schmidt said: “The approval and availability of LAVA is especially meaningful to our team because it is addressing previously unmet needs in vascular medicine, with the potential to create a significant impact on patients’ lives.
“We are delighted to expand our Sirtex product portfolio with this treatment milestone that directly furthers our mission to improve the quality and longevity of patient lives through innovative medical solutions, and we thank everyone who played a role in achieving it.”
According to Sirtex, LAVA LES has met both the primary safety and effectiveness endpoints, for the treatment of arterial haemorrhage in the peripheral vasculature, in a clinical trial.
All the study participants who received treatment with LAVA experienced no major adverse events in 30 days and 94% of the lesions met clinical success in 30 days, said Sirtex.
Sirtex is a healthcare technology company that develops SIR-Spheres Y-90 resin microspheres, a targeted radiation therapy for liver cancer, as its lead product.
Albany Medical Centre radiology department chairman Gary Siskin said: “This product’s ability to maximise the packing density within the target vessel is incredibly important, as it allows us to minimise the likelihood of a future recurrence or restoration of vessel patency.”
RUSH Medical College division of interventional radiology director and vascular and interventional radiology professor Bulent Arslan said: “The trial was an incredible success. Our goal was to achieve 70% efficacy for the existing data and outcomes, but we were able to achieve 94% efficacy. I’m overjoyed that it’s now available for all of our patients.”